MAP2 and Alzheimer disease: Western blot analysis revealed differences in expression of PDGFRβ, MAP2, Dcx, NCAM, survivin, and β-catenin (Figures 6A,B), thereby identifying these molecules as potential unique markers of AI or AD phenotypes.